Giant Cell Arteritis - Optimization of Diagnostics

Giant Cell Arteritis - Examination of the Optimal Diagnostic Pathway

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05248906

Acronym

GAME

Enrollment

110

Registered

2022-02-21

Start date

2021-03-19

Completion date

2024-01-01

Last updated

2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Giant Cell Arteritis

Keywords

Temporal artery biopsy,, Giant cell arteritis, Ultrasound, 18F-FDG PET/CT

Brief summary

Giant cell arteritis - Optimization of diagnostics

Detailed description

A prospective study. Investigating the use of ultrasound, temporal artery biopsy, biomarkers and 18F-fluorodeoxyglucose positron emission tomography-computed tomography for establishing a diagnosis of giant cell (temporal) arteritis.

Interventions

DIAGNOSTIC_TESTGiant cell arteritis

Ultrasound 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Temporal artery biopsy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Clinical suspicion of giant cell arteritis Meets the American College of Rheumatology Criteria: Age at disease onset =\> 50 years New headache Temporal artery abnormality Elevated erythrocyte sedimentation rate \>=50 mm/hour Abnomal artery biopsy

Exclusion criteria

Active cancer Use of steroid for more than a week (the prior 6 months)

Design outcomes

Primary

Measure	Time frame	Description
Giant cell arteritis	Week 26	Clinical verification of giant cell arteritis diagnosis as evaluated with a combination of ultrasound, biopsy and PET/CT.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026